ERBB2 and breast carcinoma: One of the most cited studies in this field, “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” was published in the prestigious NEW ENGLAND JOURNAL OF MEDICINE.